[1][2][3] He is currently a Distinguished Scientist and serving as Therapeutic Area Leader for Movement Disorders at F. Hoffmann-La Roche, Pharmaceutical Research and Early Development (pRED).
[16] In 1994, Brundin started his own independent research group at Lund University, Sweden, and he was promoted to full professor of neuroscience at the Faculty of Medicine in 2000.
In 2012, he moved to the USA and joined the Van Andel Institute, serving both as the Director of the Center for Neurodegenerative Science and the Head of the Laboratory for Translational Parkinson's Disease Research.
His work expanded to include the molecular mechanisms of these diseases, co-authoring with Nobel laureate Aaron Ciechanover, a 2002 review on the potential role of impaired protein degradation in neurodegenerative disorders.
[4] Starting in 2012, he served for a decade as the inaugural chair of the International Linked Clinical Trials committee, which was instrumental in conducting the largest drug repurposing program in Parkinson's Disease (PD).
[28] He is a scientific co-founder of the biotech companies Acousort AB and RYNE Biotechnology, the latter focused on induced pluripotent stem cell (iPSC)-based transplantation therapy for PD.